Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lymphoma: CLL/SLL

Join John C. Byrd, MD and Jennifer Woyach, MD from The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute as they present their expertise on a range of cases pertaining to chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (CLL).

The management of patients with CLL/SLL continues to evolve. Oncologists and hematologists need to understand the unique challenges and special considerations associated with the management of CLL/SLL. Accurate diagnosis, a thorough evaluation of indications for initiating treatment and cytogenetic abnormalities are essential to improve clinical outcomes and minimize treatment-related toxicities. Maintaining a current knowledge of recent advances and ongoing research in the field of CLL would help oncologists/hematologists incorporate novel therapies into routine clinical practice in the appropriate patient population to improve clinical outcomes.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Recognize the role of recently approved targeted therapies for patients with newly diagnosed CLL/SLL
  • Evaluate current therapeutic options for patients with relapsed/refractory CLL and effectively incorporate newly approved therapies into their treatment plan
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.59 ANCC contact hours
  • 0.50 Participation
Course opens: 
04/29/2016
Course expires: 
04/29/2017
Cost:
$0.00

John C. Byrd, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Jennifer Woyach, MD
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below have no relevant financial relationships to disclose:

Jennifer Woyach, MD

The faculty listed below have disclosed the following relevant financial relationships:

John C. Byrd, MD
Acerta Pharma: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Pharmacyclics: Grant/Research Support

NCCN Staff Disclosures 
The activity planning staff listed below has no relevant financial relationships to disclose: 
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Kathy Smith, CMP, CHCP; Jennifer McCann Weckesser 

The NCCN clinical information team listed below, who has reviewed content, has no relevant financial relationships to disclose: 
Mary Dwyer, MS; Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.59 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-056-H01-P

Available Credit

  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.59 ANCC contact hours
  • 0.50 Participation

Accreditation Period

Course opens: 
04/29/2016
Course expires: 
04/29/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing